Pyruvate Carboxylase: Structure, Function, and Disease

Pyruvate carboxylase is an enzyme found in nearly every cell of the body whose central job is to convert pyruvate, the end product of sugar breakdown, into a molecule called oxaloacetate. That one reaction might sound narrow, but it sits at a metabolic crossroads that affects blood sugar regulation, brain chemistry, insulin release, fat metabolism, and even cancer cell survival. The enzyme was first identified in 1959, and researchers are still uncovering new roles for it more than six decades later.

What It Actually Does

When your cells break down glucose for energy, one of the final products is pyruvate. From there, pyruvate can take different paths. It can be fed into the energy-producing cycle inside mitochondria (the citric acid cycle, sometimes called the TCA cycle), or it can be converted into other building blocks the cell needs. Pyruvate carboxylase handles a specific and crucial path: it attaches a carbon dioxide molecule to pyruvate to produce oxaloacetate. That reaction replenishes a key ingredient in the TCA cycle, keeping the whole energy engine running. Biochemists call this “anaplerosis,” a word that simply means refilling the cycle when its intermediates get siphoned off for other uses.

In the liver, oxaloacetate is also the starting material for making new glucose, a process the body relies on during fasting. In pancreatic beta cells, the same reaction helps regulate insulin secretion. In the brain, it enables astrocytes to produce the neurotransmitter glutamate. The enzyme does the same chemical trick everywhere, but the downstream consequences vary depending on which tissue you are looking at.

How the Enzyme Is Built and Activated

Pyruvate carboxylase is a large protein that functions as a four-subunit complex, a tetramer. Each subunit contains multiple functional regions: one region that attaches a carbon dioxide to the vitamin biotin, and another that transfers that carbon dioxide from biotin onto pyruvate. A flexible arm carrying biotin swings between these two active sites, shuttling the carbon dioxide where it needs to go.¹ Recent cryo-electron microscopy work has captured the enzyme mid-reaction, showing how the mobile biotin-carrying domain physically bridges the two reaction centers within and between subunits of the tetramer.²

What makes this enzyme unusual is that it barely works unless it receives a go-ahead signal from acetyl-CoA, a molecule that accumulates when fat is being burned or when there is an excess of fuel entering the mitochondria. Acetyl-CoA binds to a dedicated allosteric pocket on the enzyme, locking it into a shape that allows the biotin arm to swing efficiently between the two active sites.³ Without acetyl-CoA, the biotin arm wanders between several positions and rarely completes the handoff. With acetyl-CoA present, the arm is guided along a single productive path from one subunit’s carboxylation site to the neighboring subunit’s transfer site.⁴ This design is elegant because it ties the enzyme’s output to the cell’s energy status: when fuel is abundant and acetyl-CoA builds up, the enzyme ramps up production of oxaloacetate to match.

Biotin and the Vitamin Connection

Pyruvate carboxylase belongs to a small family of enzymes that all require the B vitamin biotin as a prosthetic group, meaning biotin must be physically attached to the enzyme before it can function. An enzyme called holocarboxylase synthetase handles this attachment, covalently linking biotin to pyruvate carboxylase and several other carboxylases.⁵ If holocarboxylase synthetase is deficient or if dietary biotin is severely lacking, all of these carboxylases lose activity simultaneously, a condition known as multiple carboxylase deficiency.⁶

For most people eating a normal diet, biotin deficiency is rare. But in individuals with genetic defects in holocarboxylase synthetase, the inability to activate pyruvate carboxylase and its sister enzymes produces severe metabolic crises early in life. Treatment with high-dose biotin supplements can sometimes overcome the defect by pushing the weakened enzyme to bind enough biotin.

The Liver and Blood Sugar Control

The liver is the organ most dependent on pyruvate carboxylase activity. During fasting, the liver manufactures new glucose from non-sugar precursors like lactate and the amino acid alanine. Pyruvate carboxylase catalyzes the first committed step of that gluconeogenic pathway by converting pyruvate into oxaloacetate, which is then further processed into glucose and released into the blood.

Mouse studies that knocked out pyruvate carboxylase specifically in the liver illustrate just how critical the enzyme is. These mice could manage a 24-hour fast without their blood sugar crashing, largely because other tissues compensated. But when they were placed on a ketogenic diet for a week, which stripped away almost all dietary carbohydrate, they developed severe low blood sugar. The implication is that hepatic pyruvate carboxylase is essential for maintaining glucose levels when carbohydrate intake is restricted over longer periods.⁷

Beyond gluconeogenesis, the enzyme plays a surprising role in the liver’s antioxidant defenses. When pyruvate carboxylase is absent from mouse liver, the resulting disruption to mitochondrial metabolism slashes levels of NADPH, a molecule cells use to regenerate glutathione, their main antioxidant shield. In one study, livers lacking the enzyme showed a roughly fourfold drop in the NADPH-to-NADP+ ratio, leading to increased oxidative stress and lipid damage. On a high-fat diet, these livers were more prone to inflammation, despite being paradoxically protected from some other metabolic problems like fat accumulation and high blood sugar.⁸

Within the liver itself, pyruvate carboxylase activity is not evenly distributed. Liver cells near the portal vein, which brings nutrient-rich blood from the gut, show substantially higher pyruvate carboxylase activity relative to the alternative pathway through pyruvate dehydrogenase. Measurements in rat hepatocytes found this ratio was about 2.8 times higher in the periportal zone compared to cells closer to the central vein, which helps explain why gluconeogenesis is concentrated in that region of the liver.⁹

Hormonal Signals That Turn the Gene On and Off

The amount of pyruvate carboxylase protein a cell makes is not fixed. Hormones adjust production according to the body’s needs. In liver cells, glucagon, the fasting hormone, increased pyruvate carboxylase messenger RNA about threefold within 72 hours. A chemical mimic of the intracellular signal cyclic AMP produced an even larger increase, peaking at about fourfold. Interestingly, insulin alone did not change expression, and the synthetic steroid dexamethasone had no independent effect either, though it amplified the cyclic-AMP-driven increase when both were present.¹⁰

This pattern fits the enzyme’s metabolic role neatly. During fasting, glucagon rises, insulin falls, and the liver needs to ramp up glucose production. Turning up pyruvate carboxylase gene expression ensures more enzyme is available for the job. The regulatory region of the pyruvate carboxylase gene contains a binding site for the transcription factor CREB, which transmits the cyclic-AMP signal, located roughly 1,600 base pairs upstream of the gene.

Insulin Secretion in Pancreatic Beta Cells

Pyruvate carboxylase plays a different but equally important role in the insulin-producing beta cells of the pancreas. When blood sugar rises, beta cells take up glucose, metabolize it to pyruvate, and then face a choice: send pyruvate through pyruvate dehydrogenase to generate acetyl-CoA for energy, or send it through pyruvate carboxylase to produce oxaloacetate for anaplerosis. Both routes matter for insulin release, but the pyruvate carboxylase pathway fuels a metabolic shuttle that generates NADPH, a signaling molecule that helps trigger insulin secretion.¹¹

Experiments in rat beta cells confirmed this. When researchers used RNA interference to knock down pyruvate carboxylase, insulin secretion fell significantly, along with drops in oxaloacetate, malate, ATP, and the NADPH-to-NADP+ ratio. Conversely, overexpressing pyruvate carboxylase boosted both insulin secretion and cell proliferation.¹² These findings are relevant to type 2 diabetes, where beta cells gradually lose their ability to secrete enough insulin. If pyruvate carboxylase activity declines or is dysregulated in those cells, it could contribute to the progressive failure of insulin output.

The Brain Relies on It for Neurotransmitter Supply

In the brain, pyruvate carboxylase is found almost exclusively in astrocytes, the supportive glial cells that surround neurons. Neurons themselves lack the enzyme. This matters because the brain’s two most abundant neurotransmitters, glutamate and its derivative GABA, are constantly being consumed and need to be replenished. Astrocytes handle this by using pyruvate carboxylase to produce oxaloacetate, which feeds into the TCA cycle and eventually generates alpha-ketoglutarate, the precursor to glutamate. That glutamate is then converted to glutamine and shipped to neurons for reuse.¹³

Studies in cultured astrocytes demonstrated that inhibiting pyruvate carboxylase specifically blocks the de novo synthesis of glutamate and glutamine, confirming the enzyme is essential for this process.¹⁴ This is one reason why genetic pyruvate carboxylase deficiency hits the brain so hard: without new glutamine being generated in astrocytes, the entire neurotransmitter recycling system breaks down.

When the Gene Is Broken

Pyruvate carboxylase deficiency is a rare inherited condition caused by mutations in the PC gene. Because the enzyme is so important to multiple organs, the disease manifests broadly. Three clinical forms have been described. Type A, the infantile form, typically appears in the first months of life with lactic acidosis, developmental delay, and failure to thrive. Type B, the severe neonatal form, presents at birth with overwhelming metabolic crisis, often with severe brain damage and very limited survival. Type C is considered the mildest, sometimes called the benign form, though “benign” is relative given that affected individuals still show biochemical abnormalities.¹⁵

All three forms share the underlying problem of impaired anaplerosis. Without pyruvate carboxylase filling the TCA cycle, multiple downstream pathways collapse: the liver cannot make glucose efficiently, the brain cannot generate enough glutamine, and cells throughout the body struggle to maintain their energy and biosynthetic needs. Treatment options remain limited. Some patients respond modestly to supplementation with citrate or aspartate to partially bypass the missing anaplerotic step, but no cure exists and outcomes remain poor for severe forms.

A Metabolic Advantage for Cancer Cells

Cancer researchers began paying attention to pyruvate carboxylase when they noticed that certain tumors upregulate the enzyme far beyond normal levels. The connection to cancer makes biochemical sense: rapidly dividing cells constantly drain TCA cycle intermediates to build new molecules for growth, and pyruvate carboxylase replenishes those intermediates. Tumors that cannot use glutamine efficiently for this purpose, because of either low glutamine supply or reduced glutaminase activity, appear especially reliant on pyruvate carboxylase as a backup anaplerotic route.¹⁶

Non-small-cell lung cancer provides a striking example. In these tumors, silencing pyruvate carboxylase slowed growth, and unlike in some other cancer types, the cells could not compensate by increasing glutamine use.¹⁷ Breast cancer tells a related but distinct story. Primary breast tumors do not always show elevated pyruvate carboxylase, but lung metastases derived from breast cancer do. Studies in mouse models found that depleting pyruvate carboxylase dramatically reduced pulmonary metastasis without affecting primary tumor growth, suggesting the enzyme becomes especially important when breast cancer cells colonize the lung.¹⁸ Genomic data from metastatic breast cancer patients show that roughly 16 to 30 percent carry extra copies of the PC gene, and higher expression of the gene correlates with worse survival.¹⁹

The working hypothesis is that pyruvate carboxylase gives metastatic cells metabolic flexibility: the ability to switch fuel sources and withstand oxidative stress as they adapt to new tissue environments. Cancer cells that lose pyruvate carboxylase show lower glycolytic and mitochondrial capacity and greater vulnerability to oxidative damage.²⁰ That vulnerability suggests the enzyme as a potential drug target, but getting there has proven difficult.

The Search for Drugs That Inhibit It

Given the enzyme’s roles in type 2 diabetes (excess gluconeogenesis driving high blood sugar) and cancer (supporting tumor growth and metastasis), pharmaceutical interest in pyruvate carboxylase inhibitors has been growing. A 2025 review catalogued the current landscape and described it in frank terms: no pyruvate carboxylase inhibitor has reached clinical trials. The major obstacles are potency, selectivity, and drug-like properties. Most identified inhibitors came from cell-based screening or lucky accidents rather than rational design, and none yet combines strong enough activity with the ability to spare the enzyme’s essential functions in healthy tissues.²¹

The selectivity challenge is real. Blocking pyruvate carboxylase in the liver might help control diabetic blood sugar, but shutting it down in astrocytes would starve the brain of neurotransmitter precursors, and suppressing it in beta cells could worsen insulin secretion. Any clinically useful inhibitor would need to be tissue-selective or dosed carefully enough to reduce, but not eliminate, the enzyme’s activity. Researchers are also exploring whether targeting the allosteric acetyl-CoA binding site, rather than the catalytic center, could achieve more nuanced modulation.

Measuring the Enzyme in Living Animals

One of the more inventive developments in pyruvate carboxylase research involves measuring its activity in real time, in a living animal, using a modified form of magnetic resonance imaging. The technique relies on “hyperpolarized” carbon-13-labeled pyruvate, which is injected and then tracked as it is converted into downstream products. When pyruvate carboxylase is active, the labeled pyruvate gets carboxylated into oxaloacetate, which quickly equilibrates with malate and aspartate. By detecting labeled malate and aspartate, researchers can infer how much flux is passing through the enzyme.²²

This approach has already been used to probe metabolic changes in diabetic mouse livers. Mice fed a high-fat diet showed increased exchange between labeled pyruvate and aspartate, a sign of elevated pyruvate carboxylase activity consistent with the excess glucose production characteristic of type 2 diabetes.²³ The technology is still primarily a research tool, but it represents a potential way to monitor liver metabolism noninvasively in humans, which could eventually help personalize treatments for metabolic diseases.

Across Species, the Same Core Design

Pyruvate carboxylase is found throughout the biological world, from bacteria to yeast to humans, and the enzyme’s basic architecture is remarkably conserved. In vertebrates and yeast, it forms a four-subunit complex made of identical chains, each carrying one biotin. The polypeptide chains across vertebrate species are similar in size, with molecular weights in the range of 120,000 to 130,000 per chain. Bacterial versions are noticeably different: they tend to form a two-subunit complex of about half the total mass, and each functional unit is built from two distinct polypeptides rather than one, with the biotin attached to the larger of the two.²⁴

This structural divergence between bacteria and animals has practical implications. Any drug designed to inhibit pyruvate carboxylase in human cancer cells or diabetic livers would need to be specific enough to avoid cross-reactivity with gut bacteria, and the structural differences between bacterial and mammalian forms provide at least a starting point for achieving that selectivity. Conversely, the conservation of the enzyme across all vertebrate species means that mouse and rat studies of pyruvate carboxylase function translate more directly to human biology than is the case for many other enzymes.